Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Almirall, S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Almirall, S.A. - Product Pipeline Review - 2014', provides an overview of the Almirall, S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Almirall, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Almirall, S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Almirall, S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Almirall, S.A.'s pipeline products Reasons to buy - Evaluate Almirall, S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Almirall, S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Almirall, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Almirall, S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Almirall, S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Almirall, S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Almirall, S.A. Snapshot 6 Almirall, S.A. Overview 6 Key Information 6 Key Facts 6 Almirall, S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 Almirall, S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Almirall, S.A. - Pipeline Products Glance 17 Almirall, S.A. - Late Stage Pipeline Products 17 Pre-Registration Products/Combination Treatment Modalities 17 Phase III Products/Combination Treatment Modalities 18 Almirall, S.A. - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 Almirall, S.A. - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Almirall, S.A. - Drug Profiles 22 (aclidinium bromide + formoterol fumarate) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 aclidinium bromide 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 cinitapride 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LAS-41008 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 (abediterol + inhaled corticosteroids) 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 abediterol 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LAS-41004 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LAS-190792 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LAS-40468 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 (aclidinium bromide + inhaled corticosteroid) 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 LAS-186368 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 LAS-187247 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Almirall, S.A. - Pipeline Analysis 38 Almirall, S.A. - Pipeline Products by Target 38 Almirall, S.A. - Pipeline Products by Route of Administration 40 Almirall, S.A. - Pipeline Products by Molecule Type 41 Almirall, S.A. - Pipeline Products by Mechanism of Action 42 Almirall, S.A. - Recent Pipeline Updates 44 Almirall, S.A. - Dormant Projects 49 Almirall, S.A. - Discontinued Pipeline Products 50 Discontinued Pipeline Product Profiles 50 LAS-37779 50 LAS-41007 50 Almirall, S.A. - Company Statement 51 Almirall, S.A. - Locations And Subsidiaries 53 Head Office 53 Other Locations & Subsidiaries 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 56 Disclaimer 56
List of Tables Almirall, S.A., Key Information 6 Almirall, S.A., Key Facts 6 Almirall, S.A. - Pipeline by Indication, 2014 9 Almirall, S.A. - Pipeline by Stage of Development, 2014 10 Almirall, S.A. - Monotherapy Products in Pipeline, 2014 11 Almirall, S.A. - Combination Treatment Modalities in Pipeline, 2014 12 Almirall, S.A. - Partnered Products in Pipeline, 2014 13 Almirall, S.A. - Partnered Products/ Combination Treatment Modalities, 2014 14 Almirall, S.A. - Out-Licensed Products in Pipeline, 2014 15 Almirall, S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16 Almirall, S.A. - Pre-Registration, 2014 17 Almirall, S.A. - Phase III, 2014 18 Almirall, S.A. - Phase II, 2014 19 Almirall, S.A. - Phase I, 2014 20 Almirall, S.A. - Preclinical, 2014 21 Almirall, S.A. - Pipeline by Target, 2014 39 Almirall, S.A. - Pipeline by Route of Administration, 2014 40 Almirall, S.A. - Pipeline by Molecule Type, 2014 41 Almirall, S.A. - Pipeline Products by Mechanism of Action, 2014 43 Almirall, S.A. - Recent Pipeline Updates, 2014 44 Almirall, S.A. - Dormant Developmental Projects,2014 49 Almirall, S.A. - Discontinued Pipeline Products, 2014 50 Almirall, S.A., Subsidiaries 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
